These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11383326)

  • 1. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
    Nordøy A; Hansen JB; Brox J; Svensson B
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
    Nordøy A; Svensson B; Hansen JB
    J Thromb Haemost; 2003 Apr; 1(4):690-7. PubMed ID: 12871402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
    Sirtori CR; Calabresi L; Pisciotta L; Cattin L; Pauciullo P; Montagnani M; Manzato E; Bittolo Bon G; Fellin R
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):47-55. PubMed ID: 15871851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
    Ballantyne CM; Houri J; Notarbartolo A; Melani L; Lipka LJ; Suresh R; Sun S; LeBeaut AP; Sager PT; Veltri EP;
    Circulation; 2003 May; 107(19):2409-15. PubMed ID: 12719279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
    J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
    Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
    Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
    Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.